Chemotherapy with 5-Fluorouracil and Streptozotocin in Carcinoid Tumors of Gastrointestinal Origin: Experiences with 13 Patients
| Autor: | P Vignutelli, L Amaducci, S. Derni, L Fabbri, M.P. Innocenti, Ruggero Ridolfi |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male 0301 basic medicine medicine.medical_specialty Carcinoid tumors medicine.medical_treatment 030106 microbiology Carcinoid Tumor Streptozocin 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Intestinal Neoplasms medicine Humans Pharmacology (medical) Peritoneal Neoplasms Aged Gastrointestinal Neoplasms Pharmacology Chemotherapy business.industry Middle Aged medicine.disease Streptozotocin Appendix Surgery Diarrhea Regimen Infectious Diseases medicine.anatomical_structure Appendiceal Neoplasms Oncology Chemotherapy Adjuvant Fluorouracil 030220 oncology & carcinogenesis Concomitant Colonic Neoplasms Drug Evaluation Female medicine.symptom business medicine.drug |
| Zdroj: | Journal of Chemotherapy. 3:328-331 |
| ISSN: | 1973-9478 1120-009X |
| DOI: | 10.1080/1120009x.1991.11739114 |
| Popis: | The Authors report their experiences on the treatment of 13 consecutive cases of gastro-intestinal carcinoid tumors observed over the last 11 years. The primary sites were as follows: intestine (5 cases), appendix (3 cases), colon (1 case) and peritoneum (4 cases); only 3 patients presented systemic signs. Ten patients in advanced phase were treated with a chemotherapeutic regimen containing 5-fluorouracil (5-Fu) and streptozotocin (STZ). One case was excluded from the study because of a concomitant gastric carcinoma. Of the 9 evaluable patients, two achieved partial remission (22%) with a duration of 18+ and 66 months respectively; 4 (44.5%) had stable disease for periods ranging from 7 to 40 months and 3 cases progressed. Severe toxicity (thrombocytopenia and diarrhea) occurred in 2 cases and disappeared with the suspension of therapy. The systemic signs disappeared with treatment and did not appear in 2 cases out of 3. The prospective of the employment of new drugs such as alpha-interferon and, above all, somatostatin provides hope that this uncommon disease may have an improved response rate to treatment in the future. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|